Apnea Sleep Apnea: when insurers say no, reviewers often say yes

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for Zepbound.Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Inspire device implantation (hypoglossal nerve stimulator). Continuous positive airway pressure (CPAP) has traditionally been the gold standard first-line therapy in the treatment of obstructive sleep apnea (OSA). However, failure to comply with CPAP is common because it requires a nasal or full-face mask during sleep, which many patients find intolerable. As a result, tonsillectomy with or without uvulopalatopharyngoplasty (UPPP) has been utilized as an alternative surgical option. While the procedure can be effective in properly selected patients, it can fail to reduce the AHI in a meaningful manner, and the patients who do see an improvement frequently relapse. Notably, this was the case with this patient.

Where the denial was upheld

Nature of Statutory Criteria/ Case Summary: The enrollee is requesting authorization and coverage for Continuous Positive Airway Pressure (CPAP). She has witnessed apnea, morning headaches and daytime somnolence. She was referred to the sleep clinic for evaluation for obstructive sleep apnea (OSA). The sleep study report revealed mild OSA, with an apnea–hypopnea index (AHI) of 5.9. Respiratory events consisted of episodic clusters of obstructive apneas and hypopneas. Nadir oxygenation was 87.0 percent. Time spent with an oxygenation level of less than 90 percent was 0.9 minutes. Continuous positive airway pressure (CPAP) therapy was recommended at a follow-up visit. The therapy data summary noted the enrollee had an insufficient trial on auto CPAP therapy due to less than four hours of use. A repeat CPAP trial was recommended.

Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Inspire device (hypoglossal nerve stimulator). Findings: The physician reviewer found that As noted in the medical literature, continuous positive airway pressure (CPAP) has demonstrated excellent efficacy in the treatment of patients with OSA, with long-term adherence rates approaching 50%. Although traditional upper airway surgical procedures target the anatomic component of obstruction, upper airway stimulation improves anatomic and neuromuscular pathology. There is adequate evidence in the peer-reviewed literature to support the safety, efficacy, and long-term outcome in the treatment of OSA with hypoglossal nerve stimulation.

These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for apnea sleep apnea was denied, the published record says the denial is worth fighting.